Abstract
New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen independently at multiple locations and may have functional significance. The combination of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y, K417N, and E484K mutations in the receptor binding domain (RBD) as well as mutations in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant could escape the neutralizing antibody response elicited by natural infection with earlier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa, designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing effect of convalescent plasma collected from six adults hospitalized with COVID-19 using a microneutralization assay with live (authentic) virus. Whole genome sequencing of the infecting virus of the plasma donors confirmed the absence of the spike mutations which characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and compared plasma neutralization to first wave virus which contained the D614G mutation but no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was strongly attenuated, with IC50 6 to 200-fold higher relative to first wave virus. The degree of attenuation varied between participants and included a knockout of neutralization activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody response elicited by prior natural infection. It raises a concern of potential reduced protection against re-infection and by vaccines designed to target the spike protein of earlier SARS-CoV-2 variants.
Through genomic surveillance of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), a number of new variants have recently been identified with multiple mutations in the spike glycoprotein [1, 2, 3]. We recently described the emergence of the N501Y.V2 variant in South Africa, characterised by the K417N, E484K, and N501Y mutations in the spike receptor binding domain (RBD) as well as four substitutions and a deletion in the N-terminal domain (NTD) [1]. This variant was first detected in October 2020, and has rapidly become the dominant variant in several parts of the country at a time of a rapid resurgence in infections.
The RBD is the main target of neutralizing antibodies (NAbs) elicited by SARS-CoV-2 infection, with the remaining activity directed at the NTD [4, 5, 6]. All three amino acid residues in the RBD that carry mutations in 501Y.V2 interact directly with the human angiotensin-converting enzyme 2 (hACE2) receptor and form part of the epitopes for hACE2-blocking NAbs [7]. The E484 residue specifically is a hotspot for binding of highly potent NAbs [7]. In a number of separate in vitro studies using monoclonal antibodies (mAbs), mutations at E484 have emerged as immune escape mutations, often conferring broad cross-resistance to panels of mAbs [8, 9, 10, 11]. E484K also emerged during passage with convalescent plasma, leading to substantial drops in neutralization with convalescent plasma samples [12, 13]. Using a deep mutation scanning approach to determine the effect of individual mutations on neutralization by polyclonal serum, mutations at E484 were associated with the largest drops in neutralization [14].
Here, using a microneutralization assay with authentic virus, we address the question of whether 501Y.V2 variants can escape the neutralizing response elicited by natural infection with previous variants. We outgrew and compared the neutralization of two SARS-CoV-2 501Y.V2 variants to a previously circulating variant derived from South Africa which does not have the 501Y.V2 defining mutations.
For neutralization, we used plasma samples from our ongoing longitudinal cohort study that tracks COVID-19 cases enrolled at two hospitals in Durban, South Africa [15]. We sampled participants weekly for the first month post-enrollment, and at each timepoint a blood draw and combined nasopharyngeal/oropharyngeal swab was performed to obtain both the plasma and the infecting virus.
We chose plasma from participants from the first infection wave where the infecting virus was successfully sequenced (Table S1) and where RBD binding was detected by ELISA. These viruses were from a variety of B.1 lineages circulating in South Africa and contained the D614G mutation but none of the spike mutations defining 501Y.V2 (Figure 1, see Table S2 for whole genome mutations). Plasma samples were from blood drawn approximately 1 month post-symptom onset (Table S1), shown to be close to the antibody response peak [16, 17].
(A) We obtained convalescent plasma and detected the matching infecting variant in the first SARS-CoV-2 infection wave in South Africa. A blood draw and nasopharyngeal/oropharyngeal was performed on study participants. First wave virus was outgrown from one of the participants and compared to two viruses outgrown from the second wave, which were 501Y.V2 variants. A focus forming microneutralization assay was used to quantify neutralization. (B) Phylogenetic tree and mutations of variant sequences. Variants which infected the study participants who were plasma donors only for this study are marked in blue. Sequences of variants which were outgrown are marked in yellow. Participant 039-13-0013 was both a plasma donor and the donor from whom the first wave virus was outgrown. Y-axis denotes time of sampling for viral sequencing. Table shows mutations present in Spike for the 501Y.V2 variants and the first wave virus used in the study. See Table S2 for a complete list of mutations in the viral genomes.
We outgrew first wave virus (Materials and methods) from cohort participant 039-13-0013 during the first infection wave in South Africa peaking in July 2020, and second wave 501Y.V2 virus from two samples obtained in the second wave starting November 2020 through our genomic surveillance program. We used a microneutralization live virus focus forming assay (FFA) [18]. This relies on a methylcellulose overlay to limit cell-free viral spread, resulting in a local infection focus then detected by an anti-SARS-CoV-2 Spike antibody (Materials and methods). Re-sequencing of the first 501Y.V2 variant after outgrowth revealed no changes in the RBD or NTD but a deletion in the furin cleavage site (Table S3) commonly observed after in vitro culture in Vero E6 cells [19, 20]. We designated this variant 501Y.V2.HVdF002. HV represents the outgrowth protocol which included initial outgrowth in a human H1299 cell line derivative overexpressing the ACE2 receptor, followed by a cell-to-cell infection of Vero E6 cells (Materials and methods). dF represents the deletion of the furin cleavage site. Deletion of the furin cleavage site may not affect neutralization [19]. However, we proceeded to test an additional 501Y.V2 variant. This variant, which we designated 501Y.V2.HV001, had an additional mutation, L18F, in the NTD prior to outgrowth and showed no changes in spike sequence after outgrowth.
We mixed the virus with serially diluted participant plasma, then added the mixture to Vero E6 cells and counted infection foci after 28 hours (Figure 2A, Materials and methods). There was a clear visual difference in the number of foci as a function of plasma dilution. 501Y.V2.HV001 also showed dramatically larger foci (Figure 2A).
(A) A representative focus forming assay using plasma from participant 039-13-0015. Plasma neutralization of (B) first wave virus and (C) the combined results from the two 501Y.V2 variants. Colored circles represent means and standard errors from 8 independent neutralization experiments using plasma from 6 convalescent participants who were infected by first wave variants in the first peak of the pandemic in South Africa. Correspondingly colored lines are fits of the sigmoidal equation with IC50 as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma. (D) Plasma IC50 values and ratios for first wave and 501Y.V2 variants. Knockout (KO) was scored as IC50 > 1. ND, not defined. (E) Mean and standard error across all plasma donors.
We normalized the number of foci to the number of foci in the absence of plasma on the same plate to obtain the transmission index (Tx, [21]). In this context, it is the number of foci in the presence of plasma inhibition divided by the number of foci in the absence of plasma. This controls for experiment variability between plates and experiments. The data from the FFA approximated a normal distribution (Figure S1) and we therefore used parametric statistics to describe it. We observed neutralization of the first wave virus which varied between plasma samples (Figure 2B). To obtain the IC50, we fitted the data for each participant to a sigmoidal function [22] with IC50 as the only free parameter (Materials and methods). Fitted IC50 values (Figure 2D) varied between 4× 10−3 for participant 039-13-0013 to 1× 10−4 for participants 039-13-0033 and 039-02-0015, consistent with the previously observed heterogeneity in neutralization between individuals [16, 17].
The Matlab2019b function normplot was used to assess the fit of the data (blue crosses) to a normal distribution (solid red line). Lack of pronounced curvature of the data in the range of the solid line indicates that a the data is a reasonably good fit to a normal distribution. see https://www.mathworks.com/help/stats/normplot.html for additional information.
We next determined neutralization of 501Y.V2. A decline in plasma neutralization was clearly observed (Figure 2A). T501Y.V2.HV001 also showed attenuated neutralization likely greater than that of 501Y.V2.HVdF002 (Figure S2), ruling out the in vitro generated deletion in the furin cleavage site as being responsible for escape. We combined the data for both 501Y.V2 variants. Fitted IC50 values varied between 1 × 10−3 (1:100 dilution) for plasma from participant 039-13-0033 to a complete knockout of activity for plasma from participant 039-13-0013 (Figure 2D). The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold (Figure 2D). Averaging across all participants highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants (Figure 2E).
Four sets of independent experiments were performed per 501Y.V2 - first wave pair, where the matched first wave variant results are shown to the left of the 501Y.V2 neutralization results. 501Y.V2 variant 2 contained the L18F mutation in addition to the mutations of variant 1, and did not have the furin cleavage site deletion from outgrowth in Vero E6 cells. Colored points represent means and standard errors from 4 independent experiments for each 501Y.V2 variant/first wave pair of neutralization activity of plasma from 6 convalescent participants infected by first wave viruses. Corresponding lines are fits of the sigmoidal equation with IC50 as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma.
As we have entered the second year of the SARS-CoV-2 pandemic with high levels of transmission in many parts of the world, variants with mutations at key residues in the spike glycoprotein have emerged. Here we present clear evidence using authentic SARS-CoV-2 that the 501Y.V2 variant first detected in South Africa is associated with reduced neutralization by plasma collected from patients infected in the first wave with SARS-CoV-2 variants without the 501Y.V2 defining RBD and NTD mutations. While our findings are based on plasma samples from six convalescent study participants, the relative consistency of the effect argues that the potential to escape neutralizing antibodies elicited by prior SARS-CoV-2 infection may be widespread.
The reduced neutralization is most likely related to the mutations in the spike RBD and NTD that characterize the 501Y.V2 variant. While the E484K mutation has the clearest association with immune escape, the other mutations in the RBD (K417N, N501Y) are also located within residues targeted by some class 1 and class 2 NAbs [7]. Information about the significance of NTD mutations is also emerging. NAbs targeting this site have been shown to be potent neutralizers of SARS-CoV-2 [5, 6]. The deletion at residues 242-244 is just outside an antigenic supersite loop (residues 245-264) and L18 also falls within the antigenic supersite. Furthermore, mutations at L18 and D80 have been selected during passage with mAbs [5]. Our second variant contains the L18F mutation. This may be associated with the trend to lower neutralization sensitivity relative to the first 501Y.V2 variant (Figure S2). This variant also has strikingly larger foci (Figure 2A).
The reasons for the rapid emergence and fixation of potential immune escape mutations in South Africa remain unclear. The 501Y.V2 variant was first detected in the Eastern Cape Province of South Africa, in Nelson Mandela Bay, an urban municipality with a population of just over one million. While we have no SARS-CoV-2 seroprevalence data from this area, there were 1909 excess natural deaths (approximately 1600 per million population) by the end of the first wave in mid-September (https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa). In the context of a young population (over 80 percent of the population under 50 years), this data would suggest a high attack rate from the first wave. While circumstantial, this provides some support to a hypothesis of high levels of population immunity driving the selection of variants with capacity to evade natural immunity. This area also has high HIV prevalence, and has amongst the lowest proportions of people with HIV who have viral suppression (http://www.hivdata.org.za/). We have not observed evidence of chronic SARS-CoV-2 infection in people living with HIV in our longitudinal cohort [15]. However, most cohort participants had sustained virological suppression with antiretroviral therapy (ART). We did observe altered immune dynamics after SARS-CoV-2 infection in HIV viremic participants relative to those who were virologically suppressed, and we are currently enrolling additional participants to examine SARS-CoV-2 clearance in the HIV viremic subset.
The implications of these results for re-infection and vaccine efficacy are still unclear. Our findings emphasize the need to understand whether the 501Y.V2 variant, and other similar variants, are associated with an increased rate of re-infection. Vaccines such as the Oxford/Astra Zeneca ChAdOx1 [23] and the Pfizer-BioNTech BNT162b2 [24] elicit neutralization titers in a similar range to the convalescent plasma in this study. However, these vaccines may elicit a broader antibody response and protective T cell immunity [25]. Protective T cell immunity also likely occurs following natural infection. Furthermore, it is unclear what degree of neutralization mediates protection, and infection may be particularly sensitive to inhibition at exposure [26].
In conclusion, we present data suggesting that the 501Y.V2 variant first detected in South Africa is able to escape the neutralizing antibody response elicited by natural infection with earlier variants. We expect data in the next weeks from phase 3 vaccine trials being conducted in South Africa. If the variant does have an effect on vaccine efficacy, then there may be a signal in the data from these clinical trials.
Material and methods
Ethical statement
Nasopharyngeal/oropharyngeal swab samples and plasma samples were obtained from six hospitalized adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu-Natal (reference BREC/00001275/2020). The 501Y.V2 variants were obtained from residual nasopharyngeal/oropharyngeal samples used for routine SARS-CoV-2 diagnostic testing by the National Health Laboratory Service, through our SARS-CoV-2 genomic surveillance program (BREC approval reference BREC/00001510/2020).
Whole genome sequencing, genome assembly and phylogenetic analysis
cDNA synthesis was performed on the extracted RNA using random primers followed by gene specific multiplex PCR using the ARTIC V3 protocol. Briefly, extracted RNA was converted to cDNA using the Superscript IV First Strand synthesis system (Life Technologies, Carlsbad, CA) and random hexamer primers. SARS-CoV-2 whole genome amplification was performed by multiplex PCR using primers designed on Primal Scheme (http://primal.zibraproject.org/) to generate 400bp amplicons with an overlap of 70bp that covers the 30Kb SARS-CoV-2 genome. PCR products were cleaned up using AmpureXP purification beads (Beckman Coulter, High Wycombe, UK) and quantified using the Qubit dsDNA High Sensitivity assay on the Qubit 4.0 instrument (Life Technologies Carlsbad, CA). We then used the Illumina® Nextera Flex DNA Library Prep kit according to the manufacturer’s protocol to prepare indexed paired end libraries of genomic DNA. Sequencing libraries were normalized to 4nM, pooled and denatured with 0.2N sodium acetate. 12pM sample library was spiked with 1% PhiX (PhiX Control v3 adapter-ligated library used as a control). We sequenced libraries on a 500-cycle v2 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina, San Diego, CA). We have previously published full details of the amplification and sequencing protocol [27].
We assembled paired-end fastq reads using Genome Detective 1.126 (https://www.genomedetective.com) and the Coronavirus Typing Tool [28]. We polished the initial assembly obtained from Genome Detective by aligning mapped reads to the references and filtering out low-quality mutations using bcftools 1.7-2 mpileup method. Mutations were confirmed visually with bam files using Geneious software (Biomatters Ltd, Auckland, New Zealand). All of the sequences were deposited in GISAID (https://www.gisaid.org/). We retrieved all South African SARS-CoV-2 genotypes from the GISAID database as of 11 January 2021 (N=2704). We initially analyzed South African genotypes against the global reference dataset (N=2592) using a custom pipeline based on a local version of NextStrain. The pipeline contains several python scripts that manage the analysis workflow. It performs alignment of genotypes in MAFFT [29], phylogenetic tree inference in IQ-Tree20, tree dating and ancestral state construction and annotation (https://github.com/nextstrain/ncov).
Cells
Vero E6 cells (ATCC CRL-1586, obtained from Cellonex) were propagated in complete DMEM with 10% fetal bovine serum (Hylone) containing 1% each of HEPES, sodium pyruvate, L-glutamine, and non-essential amino acids (Sigma-Aldrich). Cells were passaged every 3-4 days. H1299 cells were propagated in complete RPMI with 10% fetal bovine serum containing 1% each of HEPES, sodium pyruvate, L-glutamine, and non-essential amino acids and and passaged every second day.
H1299-E3 cell line for first passage SARS-CoV-2 outgrowth
The H1299-H2AZ clone with nuclear labelled YFP [30] was constructed to overexpress ACE2 as follows: VSVG-pseudotyped lentivirus containing the human ACE2 was generated by co-transfecting 293T cells with the pHAGE2-EF1alnt-ACE2-WT plasmid along with the lentiviral helper plasmids HDM-VSVG, HDM-Hgpm2, HDM-tat1b and pRC-CMV-Rev1b using TransIT-LT1 (Mirus) transfection reagent. Supernatant containing the lentivirus was harvested two days after infection, filtered through a 0.45µm filter (Corning) and used to spinfect H1299-H2AZ at 1000 rcf for 2 hours at room temperature in the presence of 5 µg/mL polybrene (Sigma-Aldrich). ACE-2 transduced H1299-H2AZ cells were then subcloned at the single cell density in 96-well plates (Eppendorf) in conditioned media derived from confluent cells. After 3 weeks, wells were trypsinized (Sigma-Aldrich) and plated in two replicate plates, where the first plate was used to determine infectivity and the second was stock. The first plate was screened for the fraction of mCherry positive cells per cell clone upon infection with SARS-CoV-2 mCherry expressing Spike pseudotyped lentiviral vector 1610-pHAGE2/EF1a Int-mCherry3-W produced by transfecting as above. Screening was performed using a Metamorph-controlled (Molecular Devices, Sunnyvale, CA) Nikon TiE motorized microscope (Nikon Corporation, Tokyo, Japan) with a 20x, 0.75 NA phase objective, 561 laser line, and 607 nm emission filter (Semrock, Rochester, NY). Images were captured using an 888 EMCCD camera (Andor). Temperature (37°C), humidity and CO2 (5%) were controlled using an environmental chamber (OKO Labs, Naples, Italy). The clone with the highest fraction of mCherry expression was expanded from the stock plate and denoted H1299-E3. This clone was used in the outgrowth.
Viral Outgrowth
All live virus work was performed in Biosafety level 3 containment using AHRI Institutional Biosafety Committee approved protocols for SARS-CoV-2. For first wave virus, a T25 flask (Corning) was seeded with Vero E6 cells at 2× 105 cells/ml and incubated for 18-20 hours. After 1 DPBS wash, the sub-confluent cell monolayer was inoculated with 500µL universal transport medium (UTM) diluted 1:1 with growth medium and filtered through a 0.45µM filter. Cells were incubated for 1 hour. Flask was then filled with 7mL of complete growth medium and checked daily for cytopathic effect (CPE). Four days post infection, supernatants of the infected culture were collected, centrifuged at 300 rcf for 3 minutes to remove cell debris, and filtered using a 0.45µM filter. Viral supernatant was aliquoted and stored at -80°C. For 501Y.V2 variants, we used H1299-ACE2-E3 cells for initial isolation followed by passage into Vero E6 cells. H1299-ACE2-E3 cells were seeded at 1.5 ×105 cells/ml and incubated for 18-20 hours. After 1 DPBS wash, the sub-confluent cell monolayer was inoculated with 500µL universal transport medium (UTM) diluted 1:1 with growth medium and filtered through a 0.45µM filter. Cells were incubated for 1 hour. Wells were then filled with 3mL of complete growth medium. 8 days post-infection, cells were trypsinized, centrifuged at 300 rcf for 3 minutes and resuspended in 4mL growth medium. 1mL was added to Vero E6 cells that had been seeded at t 2× 105 cells/ml 18-20 hours earlier in a T25 flask (approximately 1:8 donor-to-target cell dilution ratio) for cell-to-cell infection. Coculture of H1299-ACE2-E3 and Vero E6 cells was incubated for 1 hour and flask was then filled with 7mL of complete growth medium and incubated for 6 days. Viral supernatant was aliquoted and stored at -80°C or further passaged in Vero E6 cells as above.
Microneutralization using focus forming assay
Vero E6 cells were plated in an 96 well plate (Eppendorf) at 30,000 cells per well 1 day pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 minutes and stored at -80°C. Aliquots of plasma samples were heat-inactivated at 56°C for 30 minutes, and clarified by centrifugation at 10,000 rcf for 5 minutes, where the clear middle layer was used for experiments. Inactivated plasma was stored in single use aliquots to prevent freeze-thaw cycles. For experiments, plasma was serially diluted two-fold from 1:100 to 1:1600. Virus stocks were used at approximately 50 focus-forming units (FFU) per microwell and added to diluted plasma; antibody-virus mixtures were incubated for 1 hour at 37°C, 5% CO2 . Cells were infected with 100µL of the virus-antibody mixtures, to allow adsorption of virus. Subsequently, 100µL of a 1x RPMI 1640 (Sigma-Aldrich R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich C4888) overlay was added to the wells without removing the inoculum. Cells were fixed at 28 hours post-infection using 4% paraformaldehyde (Sigma-Aldrich) for 20 minutes. For staining of foci, a rabbit anti-Spike monoclonal antibody (mAb BS-R2B12, GenScript A02058) was used at 0.5µg/mL as the primary detection antibody. Antibody was resuspended in a permiabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich), and 0.05% tween (Sigma-Aldrich) in PBS. Plates were incubated with primary antibody overnight at 4°C, then washed with wash buffer containing 0.05% tween in PBS. Secondary goat anti-rabbit horseradish peroxidase (Abcam ab205718) was added at 1 µg/mL and incubated for 2 hours at room temperature with shaking. The TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50µL per well and incubated for 20 minutes at room temperature. Plates were then dried for 2 hours and imaged using a Metamorph-controlled Nikon TiE motorized microscope with a 2x objective. Automated image analysis was performed using a Matlab2019b (Mathworks) custom script, where focus detection was automated and did not involve user curation. Image segmentation steps were stretching the image from minimum to maximum intensity, local Laplacian filtering, image complementation, thresholding and binarization. For the second 501Y.V2 variant, a dilation/erosion step was introduced to prevent the large foci from fragmenting into smaller objects.
Statistics and fitting
All statistics and fitting were performed using Matlab2019b. Neutralization data was fit to
Here Tx is the number of foci normalized to the number of foci in the absence of plasma on the same plate at dilution D. Fit to a normal distribution using Matlab2019b function normplot, which compared the distribution of the Tx data to the normal distribution (see https://www.mathworks.com/help/stats/normplot.html).
Data Availability
All sequence data is available at GISAID.
Plasma donor characteristics
Mutation profile for the genomes of the outgrown viruses and for the infecting viruses of convalescent plasma donors
Mutation profile for the genomes of the outgrown 501Y.V2 viruses, showing the original genome produced from the nasopharyngeal swab specimen and the genomes generated following passage in VeroE6 cells
Acknowledgements
This work was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South African Medical Research Council and the Department of Science and Innovation (TdO).
Footnotes
↵§ Network for Genomic Surveillance in South Africa (NGS-SA)
Shareef Abrahams1, Luiz Carlos Junior Alcantara2, Arghavan Alisoltani-Dehkordi3,4, Mushal Allam5, Jinal N Bhiman5,6, Mary-Ann Davies7,8, Deelan Doolabh9, Susan Engelbrecht10, Vagner Fonseca11, Marta Giovanetti2, Allison J Glass6,12, Adam Godzik4, Dominique Goedhals13, Diana Hardie14, Marvin Hsiao14, Arash Iranzadeh4, Arshad Ismail5, Stephen Korsman14, Sergei L Kosakovsky Pond15, Oluwakemi Laguda-Akingba1,16, Jose Lourenco17, Gert Marais14, Darren Martin9,18, Caroline Maslo19, Koleka Mlisana20,21, Thabo Mohale5, Nokukhanya Msomi22, Innocent Mudau9, Francesco Petruccione23,24, Wolfgang Preiser10, Emmanuel James San11, Bryan Trevor Sewell25, Lynn Tyers9, Gert Van Zyl10, Anne von Gottberg5,6, Sibongile Walaza5,26, Steven Weaver15, Constantinos Kurt Wibmer5, Carolyn Williamson9,14,21, Denis York27.
1National Health Laboratory Service, Port Elizabeth, South Africa. 2Laboratorio de Flavivirus, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil. 3Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 4Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA. 5National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. 6School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 7Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. 8Western Cape Government: Health, Cape Town, South Africa. 9Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 10Division of Medical Virology at NHLS Tygerberg Hospital and Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 11KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. 12Department of Molecular Pathology, Lancet Laboratories, Johannesburg, South Africa. 13Division of Virology at NHLS Universitas Academic Laboratories, University of The Free State, Bloemfontein, South Africa. 14Division of Medical Virology at NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa. 15Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA. 16Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa. 17Department of Zoology, University of Oxford, Oxford, United Kingdom. 18Computational Biology Division, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa. 19Department of Quality Leadership, Netcare Hospitals, Johannesburg, South Africa. 20National Health Laboratory Service, Johannesburg, South Africa. 21Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. 22Discipline of Virology, University of KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences and National Health Laboratory Service, Durban, South Africa. 23Centre for Quantum Technology, University of KwaZulu-Natal, Durban, South Africa 24National Institute for Theoretical Physics (NITheP), KwaZulu-Natal, South Africa. 25Structural Biology Research Unit, Department of Integrative Biomedical Sciences, University of Cape Town, Rondebosch, South Africa. 26School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 27Molecular Diagnostics Services, Durban, South Africa.
↵§§ COMMIT-KZN Team
Moherndran Archary1, Kaylesh J. Dullabh2, Philip Goulder3,4, Guy Harling3,5, Rohen Harrichandparsad6, Kobus Herbst3,7, Prakash Jeena1, Thandeka Khoza3, Nigel Klein3,8, Henrik Kløverpris3,9,10, Alasdair Leslie3,9, Rajhmun Madansein2, Mohlopheni Marakalala3,9, Matilda Mazibuko3, Mosa Moshabela11, Ntombifuthi Mthabela3, Kogie Naidoo12, Zaza Ndhlovu3,13, Thumbi Ndung’u3,9,14,15, Kennedy Nyamande16, Nesri Padayatchi12, Vinod Patel17, Theresa Smit3, Adrie Steyn3,18, Emily Wong3,18.
1Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa. 2Department of Cardiothoracic Surgery, University of KwaZulu-Natal, Durban, South Africa. 3Africa Health Research Institute, Durban, South Africa. 4Department of Paediatrics, Oxford, UK. 5Institute for Global Health, University College London, UK. 6Department of Neurosurgery, University of KwaZulu-Natal, Durban, South Africa. 7South African Population Research Infrastructure Network, Durban, South Africa. 8Institute of Child Health, University College London, UK. 9Division of Infection and Immunity, University College London, London, UK. 10Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. 11College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 12Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. 13Ragon Institute of MGH, MIT and Harvard, Boston, USA. 14HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. 15Max Planck Institute for Infection Biology, Berlin, Germany. 16Department of Pulmonology and Critical Care, University of KwaZulu-Natal, Durban, South Africa. 17Department of Neurology, University of KwaZulu-Natal, Durban, South Africa. 18Division of Infectious Diseases, University of Alabama at Birmingham.
References
